It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new ... with various high-profile celebrities reportedly having used the drug. Internationally, it is sold in three ...
Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...
The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...
Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...
PIKE COUNTY (WBRE/WYOU) — Two men have been arrested after police say a drug bust seized various narcotics and guns ... Quantity of cocaine 100 pills containing MDMA Individually packaged THC edibles ...
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and development efforts. Since 2023, there has been rapid growth in the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results